BioLife Solutions Stock News

BOTHELL, Wash. , March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an

BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript

BioLife Solutions, Inc. is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. The company offers bioproduction tools and services for the cell and gene t

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Rod de Greef - Chairman and CEO Conference Call Participa

BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023.

BLFS, ALCO and AFCG have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2023.

BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year over year, in the quarter.

BioLife Solutions said it is divesting itself of some assets to focus on its higher-margin business. The company saw declining revenue but narrowed its losses dramatically.

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $1.71 per share a year ago.

Atrion Corp ( ATRI , Financial), a leading player in the Medical Devices & Instruments industry, is currently trading at $557 per share. The company has a market capitalization of $980.596 million and

On May 25, 2023, Aby Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc ( BLFS , Financial), sold 20,000 shares of the company's stock. This recent transaction

On May 25, 2023, Aby Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc ( BLFS , Financial), sold 20,000 shares of the company's stock. This recent transaction

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Michael Rice - Chairman & CEO Conference Call Participants Ja

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.

BioLife Solutions, a leading provider of bioproduction tools and services, is poised for growth as the demand for biologics and regenerative medicine increases. CryoStor and HypoThermosol have shown s